Hyperuricemia predicts adverse outcomes in patients with heart failure

Sanae Hamaguchi, Tomoo Furumoto, Miyuki Tsuchihashi-Makaya, Kazutomo Goto, Daisuke Goto, Takashi Yokota, Shintaro Kinugawa, Hisashi Yokoshiki, Akira Takeshita, Hiroyuki Tsutsui

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Background: Hyperuricemia is associated with worse outcomes of patients with chronic heart failure (HF). However, it is unknown in an unselected HF patients encountered in routine clinical practice. We thus assessed the impact of hyperuricemia on long-term outcomes including mortality and rehospitalization among patients hospitalized with worsening HF. Methods: The Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD) studied prospectively the characteristics and treatments in a broad sample of hospitalized HF patients and the outcomes were followed for 2.1 years after discharge. Study cohorts (n = 1869) were divided into 2 groups according to serum uric acid (UA) at discharge; ≥ 7.4 mg/dL (n = 908) and < 7.4 mg/dL (n = 961). Results: Of the total cohort of HF patients, 56% had hyperuricemia defined as UA ≥ 7.0 mg/dl. Patients with UA ≥ 7.4 mg/dL had higher rates of all-cause death, cardiac death, rehospitalization, and all-cause death or rehospitalization due to worsening HF. After multivariable adjustment, higher UA levels were a significant and independent predictor for all-cause death (adjusted hazard ratio [HR] 1.413, 95% confidence interval [CI] 1.094-1.824, P = 0.008) and cardiac death (adjusted HR 1.399, 95% CI 1.020-1.920, P = 0.037). Conclusions: Hyperuricemia was common in patients with HF encountered in clinical practice and higher UA was independently associated with long-term adverse outcomes in these patients.

Original languageEnglish
Pages (from-to)143-147
Number of pages5
JournalInternational Journal of Cardiology
Volume151
Issue number2
DOIs
Publication statusPublished - Sep 1 2011

Fingerprint

Hyperuricemia
Heart Failure
Uric Acid
Cause of Death
Confidence Intervals
Cardiology
Registries
Cohort Studies
Mortality
Serum

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Hamaguchi, S., Furumoto, T., Tsuchihashi-Makaya, M., Goto, K., Goto, D., Yokota, T., ... Tsutsui, H. (2011). Hyperuricemia predicts adverse outcomes in patients with heart failure. International Journal of Cardiology, 151(2), 143-147. https://doi.org/10.1016/j.ijcard.2010.05.002

Hyperuricemia predicts adverse outcomes in patients with heart failure. / Hamaguchi, Sanae; Furumoto, Tomoo; Tsuchihashi-Makaya, Miyuki; Goto, Kazutomo; Goto, Daisuke; Yokota, Takashi; Kinugawa, Shintaro; Yokoshiki, Hisashi; Takeshita, Akira; Tsutsui, Hiroyuki.

In: International Journal of Cardiology, Vol. 151, No. 2, 01.09.2011, p. 143-147.

Research output: Contribution to journalArticle

Hamaguchi, S, Furumoto, T, Tsuchihashi-Makaya, M, Goto, K, Goto, D, Yokota, T, Kinugawa, S, Yokoshiki, H, Takeshita, A & Tsutsui, H 2011, 'Hyperuricemia predicts adverse outcomes in patients with heart failure', International Journal of Cardiology, vol. 151, no. 2, pp. 143-147. https://doi.org/10.1016/j.ijcard.2010.05.002
Hamaguchi S, Furumoto T, Tsuchihashi-Makaya M, Goto K, Goto D, Yokota T et al. Hyperuricemia predicts adverse outcomes in patients with heart failure. International Journal of Cardiology. 2011 Sep 1;151(2):143-147. https://doi.org/10.1016/j.ijcard.2010.05.002
Hamaguchi, Sanae ; Furumoto, Tomoo ; Tsuchihashi-Makaya, Miyuki ; Goto, Kazutomo ; Goto, Daisuke ; Yokota, Takashi ; Kinugawa, Shintaro ; Yokoshiki, Hisashi ; Takeshita, Akira ; Tsutsui, Hiroyuki. / Hyperuricemia predicts adverse outcomes in patients with heart failure. In: International Journal of Cardiology. 2011 ; Vol. 151, No. 2. pp. 143-147.
@article{98fcb2fa463f479b9d262723d84051c1,
title = "Hyperuricemia predicts adverse outcomes in patients with heart failure",
abstract = "Background: Hyperuricemia is associated with worse outcomes of patients with chronic heart failure (HF). However, it is unknown in an unselected HF patients encountered in routine clinical practice. We thus assessed the impact of hyperuricemia on long-term outcomes including mortality and rehospitalization among patients hospitalized with worsening HF. Methods: The Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD) studied prospectively the characteristics and treatments in a broad sample of hospitalized HF patients and the outcomes were followed for 2.1 years after discharge. Study cohorts (n = 1869) were divided into 2 groups according to serum uric acid (UA) at discharge; ≥ 7.4 mg/dL (n = 908) and < 7.4 mg/dL (n = 961). Results: Of the total cohort of HF patients, 56{\%} had hyperuricemia defined as UA ≥ 7.0 mg/dl. Patients with UA ≥ 7.4 mg/dL had higher rates of all-cause death, cardiac death, rehospitalization, and all-cause death or rehospitalization due to worsening HF. After multivariable adjustment, higher UA levels were a significant and independent predictor for all-cause death (adjusted hazard ratio [HR] 1.413, 95{\%} confidence interval [CI] 1.094-1.824, P = 0.008) and cardiac death (adjusted HR 1.399, 95{\%} CI 1.020-1.920, P = 0.037). Conclusions: Hyperuricemia was common in patients with HF encountered in clinical practice and higher UA was independently associated with long-term adverse outcomes in these patients.",
author = "Sanae Hamaguchi and Tomoo Furumoto and Miyuki Tsuchihashi-Makaya and Kazutomo Goto and Daisuke Goto and Takashi Yokota and Shintaro Kinugawa and Hisashi Yokoshiki and Akira Takeshita and Hiroyuki Tsutsui",
year = "2011",
month = "9",
day = "1",
doi = "10.1016/j.ijcard.2010.05.002",
language = "English",
volume = "151",
pages = "143--147",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Hyperuricemia predicts adverse outcomes in patients with heart failure

AU - Hamaguchi, Sanae

AU - Furumoto, Tomoo

AU - Tsuchihashi-Makaya, Miyuki

AU - Goto, Kazutomo

AU - Goto, Daisuke

AU - Yokota, Takashi

AU - Kinugawa, Shintaro

AU - Yokoshiki, Hisashi

AU - Takeshita, Akira

AU - Tsutsui, Hiroyuki

PY - 2011/9/1

Y1 - 2011/9/1

N2 - Background: Hyperuricemia is associated with worse outcomes of patients with chronic heart failure (HF). However, it is unknown in an unselected HF patients encountered in routine clinical practice. We thus assessed the impact of hyperuricemia on long-term outcomes including mortality and rehospitalization among patients hospitalized with worsening HF. Methods: The Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD) studied prospectively the characteristics and treatments in a broad sample of hospitalized HF patients and the outcomes were followed for 2.1 years after discharge. Study cohorts (n = 1869) were divided into 2 groups according to serum uric acid (UA) at discharge; ≥ 7.4 mg/dL (n = 908) and < 7.4 mg/dL (n = 961). Results: Of the total cohort of HF patients, 56% had hyperuricemia defined as UA ≥ 7.0 mg/dl. Patients with UA ≥ 7.4 mg/dL had higher rates of all-cause death, cardiac death, rehospitalization, and all-cause death or rehospitalization due to worsening HF. After multivariable adjustment, higher UA levels were a significant and independent predictor for all-cause death (adjusted hazard ratio [HR] 1.413, 95% confidence interval [CI] 1.094-1.824, P = 0.008) and cardiac death (adjusted HR 1.399, 95% CI 1.020-1.920, P = 0.037). Conclusions: Hyperuricemia was common in patients with HF encountered in clinical practice and higher UA was independently associated with long-term adverse outcomes in these patients.

AB - Background: Hyperuricemia is associated with worse outcomes of patients with chronic heart failure (HF). However, it is unknown in an unselected HF patients encountered in routine clinical practice. We thus assessed the impact of hyperuricemia on long-term outcomes including mortality and rehospitalization among patients hospitalized with worsening HF. Methods: The Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD) studied prospectively the characteristics and treatments in a broad sample of hospitalized HF patients and the outcomes were followed for 2.1 years after discharge. Study cohorts (n = 1869) were divided into 2 groups according to serum uric acid (UA) at discharge; ≥ 7.4 mg/dL (n = 908) and < 7.4 mg/dL (n = 961). Results: Of the total cohort of HF patients, 56% had hyperuricemia defined as UA ≥ 7.0 mg/dl. Patients with UA ≥ 7.4 mg/dL had higher rates of all-cause death, cardiac death, rehospitalization, and all-cause death or rehospitalization due to worsening HF. After multivariable adjustment, higher UA levels were a significant and independent predictor for all-cause death (adjusted hazard ratio [HR] 1.413, 95% confidence interval [CI] 1.094-1.824, P = 0.008) and cardiac death (adjusted HR 1.399, 95% CI 1.020-1.920, P = 0.037). Conclusions: Hyperuricemia was common in patients with HF encountered in clinical practice and higher UA was independently associated with long-term adverse outcomes in these patients.

UR - http://www.scopus.com/inward/record.url?scp=80052334075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052334075&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2010.05.002

DO - 10.1016/j.ijcard.2010.05.002

M3 - Article

VL - 151

SP - 143

EP - 147

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

IS - 2

ER -